Hansoh Pharma Adds Veteran Lawyer Yan Jia to Board, Bolsters Governance Committees

The latest update is out from Hansoh Pharmaceutical Group Company Limited ( (HK:3692) ).

Hansoh Pharmaceutical Group has appointed veteran corporate lawyer Yan Jia as an independent non-executive director effective 26 December 2025, adding a seasoned legal and governance specialist with extensive China and international capital markets experience to its board. Yan, who holds advanced law degrees from Fudan University, Yale University and City University of Hong Kong and currently serves as a partner and Co-Chair of China Practice at Pillsbury Winthrop Shaw Pittman, has been confirmed as independent under Hong Kong listing rules and will receive an annual director’s fee of RMB360,000, with his three-year term subject to standard re-election requirements. Concurrently, Hansoh has strengthened its board oversight structure by appointing Yan as a member of both the audit committee and the environmental, social and governance committee, a move that underscores the company’s effort to enhance corporate governance, legal and compliance risk management, and board diversity as it navigates a tightly regulated pharmaceutical and capital markets environment.

The most recent analyst rating on (HK:3692) stock is a Buy with a HK$48.20 price target. To see the full list of analyst forecasts on Hansoh Pharmaceutical Group Company Limited stock, see the HK:3692 Stock Forecast page.

More about Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited is a Hong Kong‑listed pharmaceutical group focused on the research, development, manufacturing and commercialization of medicines, operating through a portfolio of subsidiaries and serving healthcare markets primarily in China.

Average Trading Volume: 8,057,398

Technical Sentiment Signal: Buy

Current Market Cap: HK$226.6B

For a thorough assessment of 3692 stock, go to TipRanks’ Stock Analysis page.